MedTrace Logo

Preventing Adverse Cardiac Events in COPD

NCT03917914 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-05-16

No results posted yet for this study

Summary

A double-blind, randomised controlled trial in participants with COPD to assess the efficacy of proactive treatment of cardiac risk in people with COPD. We hypothesise that treating known and undiagnosed CVD in COPD participants will improve both cardiac and respiratory outcomes.

Conditions

Interventions

DRUG

Bisoprolol

As in arm description

DRUG

Placebo Oral Tablet

As in arm description

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • The George Institute

    lead OTHER

Principal Investigators

  • Prof Christine Jenkins · The George Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Australia
  • India
  • New Zealand
  • Sri Lanka

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917914 on ClinicalTrials.gov